甲状腺疾病中的可溶性CD27

Soluble CD27 in thyroid disorders.

作者信息

Kallio P, Murphy E D

机构信息

Department of Medicine, The Evanston Hospital, Illinois, USA.

出版信息

J Lab Clin Med. 1998 Dec;132(6):478-82. doi: 10.1016/s0022-2143(98)90125-1.

DOI:10.1016/s0022-2143(98)90125-1

PMID:9851737

Abstract

We measured the soluble cytokine CD27 in a variety of thyroid disorders. Soluble CD27 was increased in untreated Graves' hyperthyroidism and in euthyroid ophthalmopathy. Levels of sCD27 were normal after the establishment of euthyroidism with propylthiouracil (PTU) or radio iodine in primary hypothyroidism, chronic thyroiditis, and the hyperthyroid and euthyroid phases of subacute thyroiditis. Soluble CD27 is a marker for cellular activation as in Graves' hyperthyroidism, but it is not predictive of the outcome of PTU therapy.

摘要

我们在多种甲状腺疾病中测量了可溶性细胞因子CD27。在未经治疗的格雷夫斯甲亢和甲状腺功能正常的眼病中，可溶性CD27升高。在原发性甲状腺功能减退症、慢性甲状腺炎以及亚急性甲状腺炎的甲亢期和甲状腺功能正常期，使用丙硫氧嘧啶（PTU）或放射性碘使甲状腺功能恢复正常后，sCD27水平正常。可溶性CD27是细胞活化的标志物，如在格雷夫斯甲亢中，但它不能预测PTU治疗的结果。